Salute e Benessere
XPOVIO Continues to Disrupt the Oncology Market with Expanded Indications and Strong Market Performance | DelveInsight
XPOVIO is a pioneering oral inhibitor of Exportin-1 (XPO1) and the first in Karyopharm's Selective Inhibitor of Nuclear Export (SINE) class for cancer treatment. It works by selectively binding to and blocking the nuclear export protein XPO1.
In preclinical studies, selinexor reversibly inhibits the nuclear export of Tumor Suppressor Proteins (TSPs), growth regulators, and oncogenic mRNAs by targeting XPO1. This inhibition leads to the accumulation of TSPs in the nucleus, a reduction in key oncoproteins such as c-myc and Cyclin D1, cell cycle arrest, and cancer cell apoptosis.
Selinexor has demonstrated pro-apoptotic effects in vitro in multiple myeloma cells and exhibited antitumor activity in murine xenograft models of multiple myeloma and diffuse large B-cell lymphoma. When combined with dexamethasone or bortezomib, selinexor showed synergistic cytotoxic effects in vitro and enhanced antitumor activity in vivo, including in models resistant to proteasome inhibitors.
XPOVIO is approved in the U.S. for both multiple myeloma and third-line+ (3L+) DLBCL. In 2024, the drug generated in revenue, primarily from multiple myeloma sales, leading the company to downsize due to lower-than-expected earnings.
Meanwhile, XPOVIO has been investigated in transplant-ineligible DLBCL with R-GDP since 2020, but the company has yet to release data from this trial, casting doubt on its potential impact or approval in the second-line+ (2L+) non-transplant-eligible (NTE) setting. XPOVIO is also being evaluated for myelofibrosis and endometrial cancer.
The recommended dosage of XPOVIO is 100 mg taken orally once weekly on Day 1 of each week until disease progression or unacceptable toxicity in combination with:
The recommended dosage of XPOVIO is 80 mg taken orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity in combination with dexamethasone 20 mg taken orally with each dose of XPOVIO on Days 1 and 3 of each week
The recommended dosage of XPOVIO is 60 mg taken orally on Days 1 and 3 of each week
Learn more about XPOVIO projected market size for DLBCL and multiple myeloma @
Multiple myeloma is a malignant disease marked by the uncontrolled growth of clonal plasma cells, leading to complications that result in organ dysfunction and, ultimately, death. In 2023, the total incidence of multiple myeloma across the 7MM was approximately cases, with projections indicating further growth during the forecast period.
The current treatment landscape offers a wide range of therapeutic options, including proteasome inhibitors, immunomodulators, histone deacetylase (HDAC) inhibitors, monoclonal antibodies, chemotherapy, corticosteroids, nuclear export inhibitors, and CAR-T cell therapy across different lines of treatment. Standard disease management typically involves targeted therapy and/or chemotherapy, with or without steroids, while bone marrow or stem cell transplantation may be considered in some cases. Additionally, radiation therapy and surgery are utilized under specific conditions.
In 2023, the multiple myeloma market size across the 7MM was valued at . This market is expected to experience significant growth by 2034, driven by an increase in incidence rates, expanded indications and earlier adoption of existing therapies, growing use of innovative treatments—particularly CAR-T cell therapies and anti-BCMA—an advancing pipeline, and increased investment in R&D efforts.
Discover more about the multiple myeloma market in detail @
Diffuse large B-cell lymphoma (DLBCL) is a fast-growing and the most prevalent form of Non-Hodgkin's lymphoma, which can develop within lymph nodes or in various organs outside the lymphatic system, such as the gastrointestinal tract, testes, thyroid, skin, breast, bones, or brain. In 2023, the estimated number of DLBCL incident cases across the 7MM was approximately , with projections indicating an increase by 2034.
Multidrug therapy remains the primary approach for treating DLBCL and its subtypes. Rituximab (Rituxan), usually combined with CHOP or other anthracycline-based chemotherapy regimens, is the standard first-line treatment for CD20-positive NHL in newly diagnosed patients. The widely adopted R-CHOP regimen—comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone—has shown high efficacy, often leading to a cure in early-stage DLBCL cases. However, no standardized maintenance therapy is currently available for DLBCL.
Patients with primary mediastinal B-cell lymphoma (PMBL) often require more intensive treatment, with R-CHOP increasingly being replaced by dose-adjusted EPOCH-R, a regimen that includes dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab. Additionally, the FDA has approved Rituxan Hycela (a combination of rituximab and hyaluronidase human) for use in previously untreated DLBCL following at least one full intravenous dose of rituximab.
In 2023, the DLBCL market size across the 7MM was valued at . This number is further expected to increase, driven by increasing incidence rates, advancements in targeted therapies, and a growing aging population. The adoption of CAR-T cell therapies, ADCs, and novel immunotherapies is transforming treatment paradigms. Additionally, ongoing clinical trials and regulatory approvals are expanding treatment options, further boosting market expansion.
Dive deep into an in-depth assessment of the
The DLBCL pipeline is very robust with key companies such as (LUNSUMIO (mosunetuzumab)),
(NKTR-255 + CD19 CAR-T cell therapy), (Zilovertamab vedotin),
(Cemacabtagene ansegedleucel), (Zamtocabtagene autoleucel (MB-CART2019.1)), (AZD0486, CALQUENCE (acalabrutinib)),
(Maveropepimut-S), (Iopofosine I 131 (CLR 131)),
(GLPG5101), (Rapcabtagene Autoleucel (YTB323)), (IMPT-314), (Maplirpacept (PF-07901801)), (Navtemadlin (KRT-232)), (bbT369),
(BGB-16673), (RNK05047), (Tulmimetostat (CPI-0209)),
(GEN3014), (IDP-121), (IMT-009),
(MRT-2359), (Brincidofovir (SyB V-1901)),
(AVM0703), (Obecabtagene Autoleucel (Obe-cel), AUTO3),
(KT-413), (OPB-111077), (CB-010), (ADI-001), (KITE-197, KITE-363, KITE-753, KITE-197)
(Abexinostat), (KYPROLIS (Carfilzomib)), and others involved in developing drugs.
Some of the drugs in the multiple myeloma pipeline include (Regeneron Pharmaceuticals), (AbbVie and Roche (Genentech)), (Bristol-Myers Squibb (Celgene)), (Bristol-Myers Squibb (Celgene)), (Bristol-Myers Squibb (Celgene)), (Cartesian Therapeutics), (Arcellx), (Novartis), (RAPA Therapeutics), (Roche (Genetech)), (Bristol-Myers Squibb (Juno Therapeutics, a Subsidiary of Celgene)), (Regeneron Pharmaceuticals), (BeiGene), (CARsgen Therapeutics), (C4 Therapeutics), (Heidelberg Pharma), (TeneoOne/AbbVie), (Immix Biopharma), (Active Biotech), (Galapagos), (Circio), and others.
To know more about the number of competing drugs in development, visit @
Discover how XPOVIO is shaping the multiple myeloma treatment landscape @
The market dynamics for XPOVIO are shaped by several factors, including the . As an innovative therapy , it offers a novel mechanism of action, setting it apart from traditional proteasome inhibitors, immunomodulators, and monoclonal antibodies used in multiple myeloma and lymphoma treatment.
One of the key drivers of XPOVIO's market growth is its positioning as an option for . It was initially approved in combination with dexamethasone for patients with RRMM who had received at least four prior therapies. Subsequent have expanded its market potential. However, , including CAR-T therapies, bispecific antibodies, and other novel targeted therapies, presents a significant challenge. Additionally, may impact its adoption, as XPOVIO is associated with adverse effects like nausea, fatigue, and thrombocytopenia.
Pricing and reimbursement dynamics also play a crucial role in shaping XPOVIO's market penetration. As an oral therapy, it offers , potentially improving patient adherence. However, its compared to existing therapies could limit uptake, particularly in markets with . Payers and healthcare providers weigh its cost-effectiveness against alternative therapies, influencing prescription trends. Karyopharm's pricing strategy, patient assistance programs, and efforts to demonstrating long-term benefits will be key factors in sustaining its commercial success.
Future market growth will depend on evaluating selinexor in earlier treatment lines and in combination with other agents. If positive data emerges from these studies, it could support label expansions and increased physician confidence in prescribing XPOVIO. Additionally, , international market expansion, and potential new indications beyond hematologic malignancies could further enhance its market presence. However, and evolving treatment paradigms in oncology will require Karyopharm to continually refine its positioning and market strategy.
Dive deeper to get more insight into XPOVIO's strengths & weaknesses relative to competitors @
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DLBCL companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key DLBCL companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma companies including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key multiple myeloma companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/xpovio-continues-to-disrupt-the-oncology-market-with-expanded-indications-and-strong-market-performance--delveinsight-302392516.html